Inhibition of Src family kinases overcomes anoikis resistance induced by spheroid formation and facilitates cisplatin-induced apoptosis in human mesothelioma cells. 2015

Ryoji Eguchi, and Yumiko Fujita, and Chiharu Tabata, and Hiroyasu Ogawa, and Ichiro Wakabayashi, and Takashi Nakano, and Yoshihiro Fujimori
Department of Environmental and Preventive Medicine, Hyogo College of Medicine, Nishinomiya, Hyogo 663-8501, Japan.

Malignant mesothelioma is an aggressive tumor arising from mesothelial cells of serous membranes, and forms spheroid-like cell aggregates in pleural and peritoneal effusions. We examined the levels of anoikis, apoptosis induced by the detachment of cells from the extracellur matrix, in suspension culture in the human mesothelioma cell line NCI-H2052. NCI-H2052 cells were adherent in conventional monolayer cultures, but were found to form spheroids in suspension cultures using dishes with ultra-low cell binding capacity. NCI-H2052 cells proliferated in both cultures, but the proliferation rate was markedly lower in suspension cultures than in monolayer cultures. In addition, NCI-H2052 cells in suspension cultures showed little apoptosis, suggesting that the suspension culture induces anoikis resistance. Western blot analysis revealed that suspension cultures induced activation of Src family kinases (SFK) after spheroid formation. Dasatinib, an inhibitor of multi-tyrosine kinases including SFK, abolished anoikis resistance in suspension cultures, indicating that SFK activated by spheroid formation are responsible for anoikis resistance. Cisplatin induced apoptosis in NCI-H2052 cells, but the apoptotic rate was significantly lower in suspension cultures than in monolayer cultures, suggesting that spheroid formation is involved in cisplatin resistance. Furthermore, a combination of dasatinib and cisplatin induced apoptosis more significantly than either alone in suspension cultures. These results suggest that spheroid formation induces resistance to anoikis and to cisplatin through SFK activation and that dasatinib facilitates cisplatin-induced apoptosis in human mesothelioma cells.

UI MeSH Term Description Entries
D008654 Mesothelioma A tumor derived from mesothelial tissue (peritoneum, pleura, pericardium). It appears as broad sheets of cells, with some regions containing spindle-shaped, sarcoma-like cells and other regions showing adenomatous patterns. Pleural mesotheliomas have been linked to exposure to asbestos. (Dorland, 27th ed) Mesotheliomas
D002470 Cell Survival The span of viability of a cell characterized by the capacity to perform certain functions such as metabolism, growth, reproduction, some form of responsiveness, and adaptability. Cell Viability,Cell Viabilities,Survival, Cell,Viabilities, Cell,Viability, Cell
D002945 Cisplatin An inorganic and water-soluble platinum complex. After undergoing hydrolysis, it reacts with DNA to produce both intra and interstrand crosslinks. These crosslinks appear to impair replication and transcription of DNA. The cytotoxicity of cisplatin correlates with cellular arrest in the G2 phase of the cell cycle. Platinum Diamminodichloride,cis-Diamminedichloroplatinum(II),cis-Dichlorodiammineplatinum(II),Biocisplatinum,Dichlorodiammineplatinum,NSC-119875,Platidiam,Platino,Platinol,cis-Diamminedichloroplatinum,cis-Platinum,Diamminodichloride, Platinum,cis Diamminedichloroplatinum,cis Platinum
D004357 Drug Synergism The action of a drug in promoting or enhancing the effectiveness of another drug. Drug Potentiation,Drug Augmentation,Augmentation, Drug,Augmentations, Drug,Drug Augmentations,Drug Potentiations,Drug Synergisms,Potentiation, Drug,Potentiations, Drug,Synergism, Drug,Synergisms, Drug
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000069439 Dasatinib A pyrimidine and thiazole derived ANTINEOPLASTIC AGENT and PROTEIN KINASE INHIBITOR of BCR-ABL KINASE. It is used in the treatment of patients with CHRONIC MYELOID LEUKEMIA who are resistant or intolerant to IMATINIB. (18F)-N-(2-chloro-6-methylphenyl)-2-(6-(4-(2-hydroxyethyl)piperazin-1-yl)-2-methylpyrimidin-4-ylamino)thiazole-5-carboxamide,BMS 354825,BMS-354825,BMS354825,N-(2-chloro-6-methylphenyl)-2-(6-(4-(2-hydroxyethyl)piperazin-1-yl)-2-methylpyrimidin-4-ylamino)thiazole-5-carboxamide,Sprycel,354825, BMS
D000970 Antineoplastic Agents Substances that inhibit or prevent the proliferation of NEOPLASMS. Anticancer Agent,Antineoplastic,Antineoplastic Agent,Antineoplastic Drug,Antitumor Agent,Antitumor Drug,Cancer Chemotherapy Agent,Cancer Chemotherapy Drug,Anticancer Agents,Antineoplastic Drugs,Antineoplastics,Antitumor Agents,Antitumor Drugs,Cancer Chemotherapy Agents,Cancer Chemotherapy Drugs,Chemotherapeutic Anticancer Agents,Chemotherapeutic Anticancer Drug,Agent, Anticancer,Agent, Antineoplastic,Agent, Antitumor,Agent, Cancer Chemotherapy,Agents, Anticancer,Agents, Antineoplastic,Agents, Antitumor,Agents, Cancer Chemotherapy,Agents, Chemotherapeutic Anticancer,Chemotherapy Agent, Cancer,Chemotherapy Agents, Cancer,Chemotherapy Drug, Cancer,Chemotherapy Drugs, Cancer,Drug, Antineoplastic,Drug, Antitumor,Drug, Cancer Chemotherapy,Drug, Chemotherapeutic Anticancer,Drugs, Antineoplastic,Drugs, Antitumor,Drugs, Cancer Chemotherapy
D045744 Cell Line, Tumor A cell line derived from cultured tumor cells. Tumor Cell Line,Cell Lines, Tumor,Line, Tumor Cell,Lines, Tumor Cell,Tumor Cell Lines
D018874 Spheroids, Cellular Spherical, heterogeneous aggregates of proliferating, quiescent, and necrotic cells in culture that retain three-dimensional architecture and tissue-specific functions. The ability to form spheroids is a characteristic trait of CULTURED TUMOR CELLS derived from solid TUMORS. Cells from normal tissues can also form spheroids. They represent an in-vitro model for studies of the biology of both normal and malignant cells. (From Bjerkvig, Spheroid Culture in Cancer Research, 1992, p4) Multicellular Spheroids,Cellular Spheroid,Cellular Spheroids,Multicellular Spheroid,Spheroid, Cellular,Spheroid, Multicellular,Spheroids, Multicellular
D019008 Drug Resistance, Neoplasm Resistance or diminished response of a neoplasm to an antineoplastic agent in humans, animals, or cell or tissue cultures. Antibiotic Resistance, Neoplasm,Antineoplastic Drug Resistance,Drug Resistance, Antineoplastic,Antineoplastic Agent Resistance,Neoplasm Drug Resistance,Resistance, Antineoplastic Agent,Resistance, Antineoplastic Drug

Related Publications

Ryoji Eguchi, and Yumiko Fujita, and Chiharu Tabata, and Hiroyasu Ogawa, and Ichiro Wakabayashi, and Takashi Nakano, and Yoshihiro Fujimori
February 2008, Anti-cancer drugs,
Ryoji Eguchi, and Yumiko Fujita, and Chiharu Tabata, and Hiroyasu Ogawa, and Ichiro Wakabayashi, and Takashi Nakano, and Yoshihiro Fujimori
May 2012, Carcinogenesis,
Ryoji Eguchi, and Yumiko Fujita, and Chiharu Tabata, and Hiroyasu Ogawa, and Ichiro Wakabayashi, and Takashi Nakano, and Yoshihiro Fujimori
February 2014, The Journal of investigative dermatology,
Ryoji Eguchi, and Yumiko Fujita, and Chiharu Tabata, and Hiroyasu Ogawa, and Ichiro Wakabayashi, and Takashi Nakano, and Yoshihiro Fujimori
March 2005, Oncogene,
Ryoji Eguchi, and Yumiko Fujita, and Chiharu Tabata, and Hiroyasu Ogawa, and Ichiro Wakabayashi, and Takashi Nakano, and Yoshihiro Fujimori
May 2016, American journal of physiology. Lung cellular and molecular physiology,
Ryoji Eguchi, and Yumiko Fujita, and Chiharu Tabata, and Hiroyasu Ogawa, and Ichiro Wakabayashi, and Takashi Nakano, and Yoshihiro Fujimori
July 2013, Cell death & disease,
Ryoji Eguchi, and Yumiko Fujita, and Chiharu Tabata, and Hiroyasu Ogawa, and Ichiro Wakabayashi, and Takashi Nakano, and Yoshihiro Fujimori
October 1996, Journal of leukocyte biology,
Ryoji Eguchi, and Yumiko Fujita, and Chiharu Tabata, and Hiroyasu Ogawa, and Ichiro Wakabayashi, and Takashi Nakano, and Yoshihiro Fujimori
June 2008, Cancer letters,
Ryoji Eguchi, and Yumiko Fujita, and Chiharu Tabata, and Hiroyasu Ogawa, and Ichiro Wakabayashi, and Takashi Nakano, and Yoshihiro Fujimori
July 2020, Cancers,
Ryoji Eguchi, and Yumiko Fujita, and Chiharu Tabata, and Hiroyasu Ogawa, and Ichiro Wakabayashi, and Takashi Nakano, and Yoshihiro Fujimori
August 2019, Cancers,
Copied contents to your clipboard!